Literature DB >> 27029493

Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.

Myriem Boufraqech1, Lisa Zhang1, Naris Nilubol1, Samira M Sadowski1, Shweta Kotian1, Martha Quezado2, Electron Kebebew3.   

Abstract

PURPOSE: Epithelial-to-mesenchymal transition (EMT) is important in cancer progression and metastasis. We and others have previously reported that lysyl oxidase (LOX) is overexpressed in aggressive cancers, is associated with increased mortality, and regulates EMT. However, the mechanism by which LOX mediates EMT is unknown. In this study, we investigated the effect of LOX on mediators of EMT. EXPERIMENTAL
DESIGN: We used chromatin immunoprecipitation and promoter luciferase assays to determine the target gene of LOX. To determine the effects of SNAI2 in vivo, we used our metastatic anaplastic thyroid cancer (ATC) mouse model. To investigate the effects of LOX and SNAI2 on MMPs and TIMPs, protein arrays were used. Primary tumors from patients with metastatic, breast and colon cancer, and tissue array for thyroid cancer were assessed for SNAI2 and TIMP4 expression by immunohistochemistry.
RESULTS: We found that LOX knockdown decreases SNAI2 expression in cancer cell lines. Furthermore, knockdown of LOX reduced SNAI2 expression in a metastatic mouse model of thyroid cancer. We also demonstrated that LOX binds and transactivates the SNAI2 promoter. We found a direct correlation in thyroid and breast cancer samples between LOX and SNAI2 expression. To understand how LOX/SNAI2 axis mediates these effects, we performed a comprehensive analysis of MMPs/TIMPs. LOX and SNAI2 depletion reduced TIMP4 secretion. Analysis of SNAI2 and TIMP4 expression showed overexpression of both proteins in aggressive thyroid, colon, and breast tumors.
CONCLUSIONS: Our findings provide new evidence that LOX regulates SNAI2 expression and that SNAI2-mediated TIMP4 secretion plays a role in cancer progression. Clin Cancer Res; 22(17); 4491-504. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27029493      PMCID: PMC8201910          DOI: 10.1158/1078-0432.CCR-15-2461

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

Review 1.  Matrix metalloproteinases in tumor invasion and metastasis.

Authors:  I Stamenkovic
Journal:  Semin Cancer Biol       Date:  2000-12       Impact factor: 15.707

2.  Editorial: anaplastic carcinoma of the thyroid--will aurora B light a path for treatment?

Authors:  Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2005-02       Impact factor: 5.958

3.  The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.

Authors:  Ann-Marie Baker; Thomas R Cox; Demelza Bird; Georgina Lang; Graeme I Murray; Xiao-Feng Sun; Stacey M Southall; Jon R Wilson; Janine T Erler
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

4.  Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma.

Authors:  Jin-Yuan Shih; Meng-Feng Tsai; Tzu-Hua Chang; Yih-Leong Chang; Ang Yuan; Chong-Jen Yu; Shin-Bey Lin; Geou-Yarh Liou; Meng-Larn Lee; Jeremy J W Chen; Tse-Ming Hong; Shuenn-Chen Yang; Jen-Liang Su; Yung-Chie Lee; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

5.  MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.

Authors:  Hee-Jung Moon; Joel Finney; Li Xu; David Moore; Danny R Welch; Minae Mure
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

6.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

7.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.

Authors:  Antoine E Karnoub; Ajeeta B Dash; Annie P Vo; Andrew Sullivan; Mary W Brooks; George W Bell; Andrea L Richardson; Kornelia Polyak; Ross Tubo; Robert A Weinberg
Journal:  Nature       Date:  2007-10-04       Impact factor: 49.962

8.  An in vivo mouse model of metastatic human thyroid cancer.

Authors:  Lisa Zhang; Kelli Gaskins; Zhiya Yu; Yin Xiong; Maria J Merino; Electron Kebebew
Journal:  Thyroid       Date:  2014-03-10       Impact factor: 6.568

9.  A molecular role for lysyl oxidase in breast cancer invasion.

Authors:  Dawn A Kirschmann; Elisabeth A Seftor; Sheri F T Fong; Daniel R C Nieva; Colleen M Sullivan; Elijah M Edwards; Pascal Sommer; Katalin Csiszar; Mary J C Hendrix
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.

Authors:  Lisa Zhang; Yaqin Zhang; Amit Mehta; Myriem Boufraqech; Sean Davis; Jing Wang; Ze Tian; Zhiya Yu; Matthew B Boxer; Jeffrey A Kiefer; John A Copland; Robert C Smallridge; Zhuyin Li; Min Shen; Electron Kebebew
Journal:  Oncotarget       Date:  2015-04-20
View more
  31 in total

1.  Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Authors:  Myriem Boufraqech; Dhaval Patel; Naris Nilubol; Astin Powers; Timothy King; Jasmine Shell; Justin Lack; Lisa Zhang; Sudheer Kumar Gara; Viswanath Gunda; Joanna Klubo-Gwiezdzinska; Suresh Kumar; James Fagin; Jeffrey Knauf; Sareh Parangi; David Venzon; Martha Quezado; Electron Kebebew
Journal:  Thyroid       Date:  2018-12-28       Impact factor: 6.568

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  LOX and ACSL5 as potential relapse markers for pancreatic cancer patients.

Authors:  Weidong Ma; Ting Li; Si Wu; Jian Li; Xiuchao Wang; Hui Li
Journal:  Cancer Biol Ther       Date:  2019-02-03       Impact factor: 4.742

4.  Lysyl Oxidases Expression and Breast Cancer Progression: A Bioinformatic Analysis.

Authors:  Sofia Ramos; Sandra Ferreira; Ana S Fernandes; Nuno Saraiva
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

5.  Low extracellular lysyl oxidase expression is associated with poor prognosis in patients with prostate cancer.

Authors:  Wei Zheng; Xuejian Wang; Qiwei Chen; Kun Fang; Lina Wang; Feng Chen; Xiancheng Li; Ziyao Li; Jianbo Wang; Yingxi Liu; Deyong Yang; Xishuang Song
Journal:  Oncol Lett       Date:  2016-09-12       Impact factor: 2.967

6.  Antcin-H Isolated from Antrodia cinnamomea Inhibits Renal Cancer Cell Invasion Partly through Inactivation of FAK-ERK-C/EBP-β/c-Fos-MMP-7 Pathways.

Authors:  Kun-Yuan Chiu; Tzu-Hsiu Chen; Chi-Luan Wen; Jin-Mei Lai; Chi-Chih Cheng; Hsiang-Chun Liu; Shih-Lan Hsu; Yew-Min Tzeng
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-02       Impact factor: 2.629

7.  Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.

Authors:  Domenico Bellomo; Suzette M Arias-Mejias; Chandru Ramana; Joel B Heim; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Mark R Pittelkow; David J DiCaudo; Barbara A Pockaj; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves
Journal:  JCO Precis Oncol       Date:  2020-04-14

8.  Lysyl oxidase activates cancer stromal cells and promotes gastric cancer progression: quantum dot-based identification of biomarkers in cancer stromal cells.

Authors:  Chunwei Peng; Jiuyang Liu; Guifang Yang; Yan Li
Journal:  Int J Nanomedicine       Date:  2017-12-27

9.  Molecular Fingerprint for Terminal Abdominal Aortic Aneurysm Disease.

Authors:  Gabor Gäbel; Bernd H Northoff; Irina Weinzierl; Stefan Ludwig; Irene Hinterseher; Wolfgang Wilfert; Daniel Teupser; Stefan A Doderer; Hendrik Bergert; Frank Schönleben; Jan H N Lindeman; Lesca M Holdt
Journal:  J Am Heart Assoc       Date:  2017-11-30       Impact factor: 5.501

10.  Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.

Authors:  Ozge Saatci; Aysegul Kaymak; Umar Raza; Pelin G Ersan; Ozge Akbulut; Carolyn E Banister; Vitali Sikirzhytski; Unal Metin Tokat; Gamze Aykut; Suhail A Ansari; Hayriye Tatli Dogan; Mehmet Dogan; Pouria Jandaghi; Aynur Isik; Fatma Gundogdu; Kemal Kosemehmetoglu; Omer Dizdar; Sercan Aksoy; Aytekin Akyol; Aysegul Uner; Phillip J Buckhaults; Yasser Riazalhosseini; Ozgur Sahin
Journal:  Nat Commun       Date:  2020-05-15       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.